The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Addressing nephrotoxicity in agents commonly used to treat multiple myeloma
Nelson Leung, MD, Mayo Clinic, Rochester, MN, discusses how lenalidomide and carfilzomib are associated with renal toxicity when used in the treatment of multiple myeloma. Dr Leung also reports on the results of a recent review which found no evidence that bortezomib causes any significant renal toxicity. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
